Madrigal Pharmaceuticals

Liver

Biotech

Madrigal boosts MASH pipeline with $1B biobucks Arrowhead deal

Madrigal Pharmaceuticals has struck a backloaded deal for the global license to an Arrowhead Pharmaceuticals phase 1 asset for patients with MASH.

Will Maddox May 5, 2026 10:40am

Lifeline

Midsize biotechs form coalition to fight against MFN policy

Feb 25, 2026 1:05pm

liver

Madrigal pens $4.4B deal for siRNA drugs in fresh Rezdiffra play

Feb 11, 2026 7:40am

liver

Madrigal pays Pfizer $50M for MASH drug with combo potential

Jan 9, 2026 10:50am

ChatGPT said Low-poly magenta liver model centered on a pale blue background patterned with sketchy dollar signs suggestin

Fierce Pharma

Big Pharma bets big on MASH with a new combo playbook

Oct 17, 2025 9:30am

liver

Madrigal pens $2B deal for CSPC's GLP-1, eyes Rezdiffra pairing

Jul 30, 2025 7:35am